Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy by Tajan, Mylène et al.
ARTICLE
Serine synthesis pathway inhibition cooperates
with dietary serine and glycine limitation
for cancer therapy
Mylène Tajan1, Marc Hennequart1, Eric C. Cheung1, Fabio Zani1, Andreas K. Hock2,3, Nathalie Legrave1,
Oliver D. K. Maddocks 4, Rachel A. Ridgway2, Dimitris Athineos 2, Alejandro Suárez-Bonnet 5,
Robert L. Ludwig1, Laura Novellasdemunt1, Nikolaos Angelis1, Vivian S. W. Li 1, Georgios Vlachogiannis6,7,
Nicola Valeri6,7,8, Nello Mainolfi9, Vipin Suri9, Adam Friedman9, Mark Manfredi9, Karen Blyth 2,4,
Owen J. Sansom 2,4 & Karen H. Vousden 1✉
Many tumour cells show dependence on exogenous serine and dietary serine and glycine
starvation can inhibit the growth of these cancers and extend survival in mice. However,
numerous mechanisms promote resistance to this therapeutic approach, including enhanced
expression of the de novo serine synthesis pathway (SSP) enzymes or activation of onco-
genes that drive enhanced serine synthesis. Here we show that inhibition of PHGDH, the first
step in the SSP, cooperates with serine and glycine depletion to inhibit one-carbon meta-
bolism and cancer growth. In vitro, inhibition of PHGDH combined with serine starvation
leads to a defect in global protein synthesis, which blocks the activation of an ATF-4 response
and more broadly impacts the protective stress response to amino acid depletion. In vivo, the
combination of diet and inhibitor shows therapeutic efficacy against tumours that are
resistant to diet or drug alone, with evidence of reduced one-carbon availability. However, the
defect in ATF4-response seen in vitro following complete depletion of available serine is not
seen in mice, where dietary serine and glycine depletion and treatment with the PHGDH
inhibitor lower but do not eliminate serine. Our results indicate that inhibition of PHGDH will
augment the therapeutic efficacy of a serine depleted diet.
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Cancer cells adapt their metabolism to support growth andsurvival, leading to various dependencies and vulner-abilities that could be targeted for therapy1. While these metabolic alterations are dictated by numerous factors, includingthe genetic alterations in the tumour and the tumour environ-ment or tissue of origin, recent attention has focused on the role
of serine metabolism in supporting cancer cell growth2. Serine
and glycine (which is produced from serine by the SHMT1/2
reaction) contribute to a number of important processes,
including protein, nucleotide and lipid synthesis, the generation
of antioxidant defense through glutathione and NADPH synth-
esis and the provision of one-carbon units for the folate cycle and
methylation reactions3. Consequently, cancer cells have been
shown to be highly dependent on serine, and antifolates that
include dihydrofolate reductase, thymidylate synthase and glyci-
namide ribonucleotide formyltransferase inhibitors, have been
successfully used as therapeutic drugs4. The earliest example, the
dihydrofolate reductase inhibitor methotrexate, has been used to
treat several different types of cancer including haematological
malignancies, breast cancer and osteosarcoma for over 70 years,
with newer drugs targeting this pathway under constant devel-
opment4–6. As a non-essential amino acid, serine can be taken up
from the extracellular environment or synthesised de novo by
cells using the serine synthesis pathway (SSP). Tissue culture
experiments have shown that many cancer cells avidly consume
serine and depend on an exogenous source of serine for optimal
growth7–10. However, most cells can adapt to serine starvation by
activating flux through the SSP. Serine is an activator of PKM2,
the final step in glycolysis, and decreased PKM2 activity under
serine depleted conditions allows for the diversion of glycolytic
intermediates into the SSP11,12. This response is coordinated with
an ATF-4 and histone methyltransferase G9A-dependent activa-
tion of the three enzymes of the SSP10,12,13, which allow most
cancer cells to survive and continue to proliferate following serine
starvation. The efficacy with which cancer cells can adapt to the
loss of exogenous serine depends on several factors. Some cancers
acquire an amplification or overexpression of PHGDH – the first
step in the SSP – and these cells tend to be less affected by serine
starvation14–16. Similarly, activation of oncogenes such as KRAS,
MYC, MDM2 and NRF210,17–19 can lead to an increase in SSP
enzyme expression, also allowing cells to become resistant to
depletion of exogenous serine. Conversely, although the p53
tumour suppressor protein can inhibit PHGDH expression20, loss
of p53 also makes cells more vulnerable to increased ROS that
accompanies the switch to de novo serine synthesis, resulting in a
decreased survival in serine free medium7.
Several studies have shown that dietary serine limitation can
slow tumour growth in vivo7,17,21–24. Mice fed with a serine and
glycine free diet show a decrease in circulating serine and glycine
levels and this approach can retard the development and pro-
gression of tumours in both xenograft and genetically engineered
mouse models. As predicted by in vitro studies, the survival
response to dietary serine and glycine restriction was enhanced by
interference with antioxidant defence mechanisms17. Activation
of KRAS or enhanced expression of PHGDH, on the other hand,
resulted in an increase in de novo serine synthesis which limited
the response to the serine and glycine free diet17,23. Under these
conditions, it is possible that inhibition of the SSP will cooperate
with dietary serine and glycine restriction to improve therapeutic
efficacy. Indeed, a recent study has shown cooperation between
deletion of PSAT1 (the second step in the serine synthesis
pathway) and dietary serine depletion in the inhibition of Myc-
driven liver cancer25.
Several small molecule inhibitors of PHGDH that inhibit de
novo serine synthesis and retard the growth of cancer cells that
are dependent on this pathway have been generated26–28. This
first generation of inhibitors showed relatively weak potency,
leading to the development of more active, second generation
inhibitors, which were effective to limit cancer cell growth in vitro
Fig. 1 PHGDH inhibition cooperates with serine/glycine depletion to
impede tumour growth in vitro. a As a non-essential amino acid, serine
can be taken up from the environment or newly synthesised through the
serine synthesis pathway (SSP). The SSP consists of a three-step enzymatic
reaction starting with the NAD+-dependent oxidation of the glycolytic
intermediate 3-phosphoglycerate (3-PG) to 3-phosphohydroxypyruvate (3-
PHP). This first reaction is catalysed by phosphoglycerate dehydrogenase
(PHGDH), an enzyme that can be efficiently targeted by the
pharmacological compound PH755. The 3-PHP produced during the
PHGDH reaction is then converted into 3-phosphoserine (3-PS) by
phosphoserine aminotransferase 1 (PSAT1) in a glutamate-dependent
transamination reaction. Finally, phosphoserine phosphatase (PSPH)
catalyses the hydrolysis of 3-PS to produce serine. Serine is involved in
numerous metabolic pathways including nucleotide synthesis or
glutathione synthesis, a major antioxidant for the cells. Serine availability
can thus be targeted by depleting it from the extracellular environment or
by inhibition of the SSP using PH755. b Growth curves of colon cancer cell
lines grown in complete medium (CM) or equivalent medium lacking serine
and glycine (-SG) and treated or not with 10 µM PH755. Data are presented
as mean ± SEM of triplicate cultures and are representative of at least two
independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001; two-way ANOVA with Tukey’s post hoc test).
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under serine deprivation but were not suitable for use in vivo29.
More recently, a highly potent, selective and reversible PHGDH
inhibitor, PH755, has been reported to prevent the flux of labelled
glucose into serine in LPS stimulated macrophages and improve
the survival of mice exposed to LPS-induced endotoxemia30. This
inhibitor has also been shown to be effective to limit tumour
growth in vivo24,31. In this study we examine the cooperation
between serine and glycine starvation (-SG) and PHGDH inhi-
bition (PHGDHi), demonstrating a reduction of tumour
cell growth in vitro and in vivo. Our data support the therapeutic
potential of combining dietary serine and glycine restriction with
a small molecule inhibitor of PHGDH.
Results
PHGDHi/-SG impedes growth of tumour cell lines. Cells can
take up exogenous serine or synthesise serine from the glycolytic
intermediate 3-phosphoglycerate (3-PG), using the serine synth-
esis pathway (Fig. 1a). To assess the relative contribution of each
of these pathways to the growth of cells in culture, we measured
the proliferation of a series of colorectal cancer cell lines grown in
complete medium (CM), medium lacking serine and glycine
(-SG), CM with PH755 (a PHGDH inhibitor) or a combination of
-SG plus PH755. As noted previously14,27, the response to serine
and glycine starvation varied between cell lines ranging from
RKO, HT-29 and SW48 cells that showed a significant dependence
on exogenous serine and glycine for proliferation, to DLD-1, LoVo,
CACO-2 and MDA-MB-468 cells (a breast cancer line previously
shown to carry PHGDH amplification) that were not affected by
lack of serine and glycine in the medium (Fig. 1b and Supple-
mentary Figure 1a). There was a trend for colorectal cancer cell
lines carrying KRAS mutation (HCT-15, HCT116, DLD-1, LoVo
and SW480) to be more resistant to serine and glycine withdrawal
compared to those cell lines carrying BRAF mutations (RKO, HT-
29, SW1417 and CL-34), although SW620 (KRAS mutant) and
VACO5 (BRAF mutant) were exceptions to this trend (Fig. 1b and
Supplementary Figure 1a). While these results are broadly in line
with the previously reported role of activated KRAS in supporting
de novo serine synthesis17, it is clear that other genetic alterations –
such as amplification of PHGDH in MDA-MB-468 cells14 – also
contribute to the dependence of cancer cells on a supply of exo-
genous serine. Treatment of the cells with PH755 in complete
medium had no clear effect on the proliferation rate of the cells,
indicating that at this concentration, the inhibitor has no non-
specific inhibitory effect on cell growth. However, combining -SG
medium with PH755 completely inhibited the growth of all the cell
lines tested (Fig. 1b and Supplementary Figure 1a).
PHGDHi/-SG limits DNA synthesis, survival and organoid
growth. Accompanying the lack of proliferation was a strong
reduction of BrdU incorporation into newly synthesised DNA
after 48 h incubation with -SG medium plus PH755, compared to
either treatment alone (Fig. 2a and Supplementary Figure 1b).
The decrease in cells undergoing S-phase was accompanied by an
accumulation of cells in G2/M phase (Supplementary Figure 1b
and Supplementary Figure 1c) and an increase in the proportion
of SubG1 cells in the double-treated condition, indicating an
increase in cell death (Fig. 2b). The appearance of cleaved
caspase-3 confirmed the induction of apoptosis in cells cultured
in -SG medium and treated with PH755 (Fig. 2c). Using uni-
formly labelled glucose, we showed that cells grown in the pre-
sence of exogenous serine diverted little glucose into serine and
glycine synthesis, as reflected by the negligible accumulation of m
+ 3 serine and m+ 2 glycine (Fig. 2d and Supplementary Figure
1d), regardless of the presence or absence of PH755. Of note,
these cells maintained much higher overall intracellular serine
and glycine levels than cells grown in the -SG medium (Supple-
mentary Figure 1e). When starved of serine and glycine, all the
cell lines showed a clear increase in de novo serine synthesis, as
indicated by the accumulation of m+ 3 labelled serine and m+ 2
labelled glycine (Fig. 2d and Supplementary Figure 1d). Inter-
estingly, this response was weaker in the HT-29 cells, consistent
with their lower ability to proliferate in the absence of exogenous
serine. However, treatment of the cells with PH755 completely
blocked de novo synthesis of serine and glycine, both in complete
medium and under serine and glycine starvation (Fig. 2d and
Supplementary Figure 1d), demonstrating the efficiency of this
inhibitor in blocking PHGDH activity and the SSP. To further
verify the specificity of PH755, we tested the effect of genetic
deletion of PHGDH. DLD-1 cells showed a strong induction of
PHGDH expression in response to serine and glycine starvation,
which was much less robust in HT-29 cells – consistent with the
relative ability of these cell lines to proliferate in the absence of
exogenous serine and glycine (Supplementary Figure 1f). Pro-
liferation of these cells following CRISPR-mediated deletion of
PHGDH (Supplementary Figure 1f) essentially mirrored that seen
following PH755 treatment (Fig. 1b), supporting the function of
PH755 as an inhibitor of PHGDH.
Cells grown in 2D on plastic can show different metabolic
requirements compared to cells grown under more physiologi-
cally relevant conditions, and so we examined the effect of serine
and glycine depletion and PH755 treatment on intestinal tumour
organoids derived from Vil1-creER;Apcfl/fl (Apc) or Vil1-creER;
Apcfl/fl;KrasG12D/+ (Apc Kras) mice (Fig. 2e and Supplementary
Figure 2a). As shown previously, organoids derived from Apc
mutant tumours showed some sensitivity to serine and glycine
depletion, which was not evident in Apc/Kras mutant organoids.
Consistent with the observations in 2D cell lines, treatment with
PH755 alone did not impact the growth of Apc or Apc/Kras
organoids. However, the combination of serine and glycine
starvation and PH755 treatment very effectively inhibited the
growth of both Apc and Apc/Kras organoids (Fig. 2e and
Supplementary Figure 2a). Of note, this effect was not restricted
to cancer-derived intestinal organoids, as a substantial reduction
in growth was also observed in normal small intestine organoids
treated with the combination treatment (Supplementary Figure
2b). To validate the effect of the double treatment in human cells,
we tested four patient-derived colorectal cancer organoids with
different KRAS status (C-001: WT, C-004: deletion, R-006:
Gly12Asp and R-008: Gly13Asp)32. While -SG or PH755
treatment alone did not have any obvious impact on proliferation,
in each case, the combination of drug and inhibitor greatly
decreased organoid growth, regardless of KRAS status (Supple-
mentary Figure 2c). While we see a trend for cells with KRAS
mutations to be less sensitive to serine and glycine starvation
alone, exceptions are likely to reflect other changes that influence
the serine synthesis pathway such as PHGDH amplification.
PHGDHi/-SG treatment inhibits purine and GSH synthesis.
Serine is involved in numerous metabolic pathways, including the
provision of one-carbon units and glycine for purine synthesis and
the maintenance of redox homeostasis through glutathione pro-
duction. The contribution of de novo synthesised serine to these
pathways can be assessed by following the fate of uniformly car-
bon labelled glucose (Fig. 3a). As expected, cells grown in the
presence of serine and glycine showed little evidence of the use of
de novo synthesised serine for ATP or GTP synthesis (Fig. 3b), the
majority of label (m+ 5) deriving from ribose synthesised through
the pentose phosphate pathway (Fig. 3a). Under serine and glycine
starvation, cells that were best able to adapt to these conditions
(HCT116, DLD-1 and MDA-MB-468) accumulated m+ 6 to
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Fig. 2 PHGDH inhibition cooperates with serine/glycine depletion to limit DNA synthesis, survival and organoid growth. a Percentage of BrdU positive
cells in HCT116 and DLD-1 cells grown in CM or -SG medium ±10 µM PH755 for 48 h followed by a 5-h incubation with 10 µM BrdU. Data represents mean
± SEM of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA with Tukey’s post hoc test). b Percentage of SubG1 cells in
HCT116 and DLD-1 cells grown in CM or -SG medium ±10 µM PH755 for 48 h. Data represents mean ± SEM of five independent experiments (**p < 0.01,
***p < 0.001, one-way ANOVA with Tukey’s post hoc test). c Cells were grown in CM or -SG medium supplemented or not with 10 µM PH755 for 2 days
(HCT116) or 3 days (DLD-1). Western blots show the expression of cleaved Caspase-3 and Caspase-3. Membrane was reprobed with vinculin as a loading
control. Data are representative of three independent experiments. d Intracellular serine level in cells grown in CM or -SG medium ±10 µM PH755
containing U-[13C]-glucose was measured by LC-MS. Metabolite percentages are represented as mean ± SEM of triplicate cultures and are representative
of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Tukey’s post hoc test). e Intestinal tumour
organoids derived from Vil1-creER;Apcfl/fl (Apc) and Vil1-creER;Apcfl/fl;KrasG12D/+ (Apc Kras) mice were grown in CM or -SG medium supplemented or not
with 10 µM PH755. Left panel: representative pictures of the organoids are shown before (day 0) and 2 days after medium change. Right panel:
quantification of organoid diameter 2 (Apc) or 4 days (Apc Kras) after medium change. Data are presented as mean ± SEM (n= number of organoids
measured per condition; Apc: CM: n= 113, CM+ PH755: n= 200, -SG: n= 190, -SG+ PH755: n= 158; Apc Kras: CM: n= 149, CM+ PH755: n= 134, -SG:
n= 134, -SG+ PH755: n= 78) and are representative of at least two independent experiments (***p < 0.001, ****p < 0.0001; one-way ANOVA with
Tukey’s post hoc test). Scale bar represents 200 μm.
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m+ 9 labelled purines, consistent with the incorporation of
labelled serine generated through the SSP (Fig. 3b). As expected,
serine and glycine starvation with PH755 treatment effectively
inhibited synthesis of ATP and GTP (Fig. 3b). Glutathione can
be labelled from glucose derived glycine (m+ 2) or glutamate
(m+ 2; Fig. 3a), although under these conditions the generation of
m+ 2 glutamate was not impacted by PH755 treatment in most of
the cell lines tested (Supplementary Figure 3a). The increase in the
proportion of m+ 2 and m+ 4 labelled glutathione detected in
response to the removal of exogenous serine and glycine is
therefore likely to reflect the increase in SSP activity and pro-
duction of labelled glycine, a response that was blocked by treat-
ment with PH755 (Fig. 3c). Importantly, the inability of the double-
treated cells to newly synthetise purines and glutathione was evident
as early as 3- or 6-h post-treatment, demonstrating that this response
represents a primary effect of the combination treatment (Supple-
mentary Figure 3b). Of note, total purine and GSH levels were not
decreased in the double-treated cells compared to the cells grown in
-SG medium, probably reflecting the lack of consumption of these
metabolites when proliferation is inhibited (Supplementary Figure
3c). These results confirm that metabolic pathways that are depen-
dent on serine and critical for the growth of cancer cells are efficiently
inhibited by a combination of serine and glycine starvation and the
PHGDH inhibitor.
Metabolic rescue of PHGDHi/-SG treated cells. All cells
deprived of serine and glycine and treated with PH755 showed a
strong growth inhibition (Figs. 1b, 2e, Supplementary Figure 1a
and Supplementary Figure 2a–c). While supplementation of the
double-treated cells with either formate (to replenish the one-
carbon cycle) or glycine alone did not restore growth, addition of
formate and glycine effectively rescued proliferation (Fig. 4a).
This proliferation rescue was accompanied by the recovery of
ATP and GTP synthesis (Fig. 4b), and the partial restoration of
the pool of unlabelled serine (Fig. 4c). Using labelled glycine, we
were able to demonstrate that this pool of serine is generated
from glycine and one-carbon units provided by formate, a
Fig. 3 Combining PHGDH inhibition with serine/glycine depletion inhibits purine and glutathione synthesis. a Scheme representing the fate of uniformly
carbon labelled glucose (m+ 6) into purine and glutathione synthesis. Glucose is converted through the pentose phosphate pathway into ribose-5-
phosphate, a five-carbon sugar (m+ 5), that will be added to purine bases to form purine nucleosides. Purine rings also contain two one-carbon units and
an intact glycine that can both come from serine metabolism. Serine is synthesised from the glycolytic intermediate 3-PG, producing an m+ 3 isotopomer
from uniformly labelled glucose. Serine (m+ 3) can generate labelled glycine (m+ 2) and labelled one-carbon units (m+ 1). The combination of labelled
ribose phosphate, glycine and one-carbon units can thus generate m+ 5 and greater labelled purines. While m+ 5 labelled purines represent a
contribution of glucose to ribose synthesis alone, m+ 6–9 labelled purines are likely to represent a contribution from de novo synthesised serine.
Glutathione is made from glycine, glutamate (both can be m+ 2 labelled from glucose) and cysteine. The main isotopomer (m+ 2) of glutathione is likely
to be derived from m+ 2 glycine with the m+ 4 labelling reflecting incorporation of m+ 2 glycine and m+ 2 glutamate. b, c Intracellular ATP and GTP
levels (b) or GSH level (c) in HT-29, HCT116, DLD-1 and MDA-MB-468 cells grown in CM or -SG medium ±10 µM PH755 containing U-[13C]-glucose were
measured by LC-MS. Metabolite percentages are represented as mean ± SEM of triplicate cultures and are representative of three independent
experiments. Statistics have been performed by comparing the sum of m+ 6–9% of metabolite pool for ATP and GTP and the sum of m+ 2–4% of
metabolite pool for GSH between experimental groups (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Tukey’s post hoc test).
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response that is made more evident following the addition of a
pulse of unlabelled serine to allow the labelled serine to accu-
mulate (Fig. 4d). These results show that the inhibition of pro-
liferation is a direct effect of inhibition of de novo serine synthesis
by PH755, and not a response to any off-target toxicity. The
specificity of the metabolic defect induced by PH755 was further
supported by the similarity of the response to genetic deletion of
PHGDH (Supplementary Figure 4a–c).
Fig. 4 Formate and glycine supplementation rescues cancer cells grown in serine/glycine free medium in presence of the PHGDH inhibitor.
a Proliferation assay of HT-29 and HCT116 cells grown in -SG medium or -SG medium+ 10 µM PH755 supplemented or not with 1 mM sodium formate
(For), 0.4 mM glycine (Gly) or both (For/Gly). Data are presented as mean ± SEM of triplicate cultures and are representative of three independent
experiments (*p < 0.05, **p < 0.01; two-way ANOVA with Tukey’s post hoc test). b, c HCT116 cells were grown in -SG medium or -SG medium+ 10 µM
PH755 supplemented or not with 1 mM sodium formate (For), 0.4 mM glycine (Gly) or both (For/Gly) in presence of U-[13C]-glucose. b ATP and GTP
levels were measured by LC-MS. Metabolite percentages are represented as mean ± SEM of triplicate cultures and are representative of two independent
experiments. c Serine level was measured by LC-MS. Data are presented as mean ± SEM of triplicate cultures and are representative of two independent
experiments (*p < 0.05, **p < 0.01, ****p < 0.0001; one-way ANOVA with Tukey’s post hoc test). d HT-29, HCT116 and DLD-1 cells were grown in -SG
medium+ 10 µM PH755 supplemented with 1 mM sodium formate and 0.4mM glycine for 24 h in presence of 13C215N1-Glycine for the last hour. 13C215N1-
Serine intracellular level was measured by LC-MS after adding a pulse of unlabelled 1 mM serine in the extracellular medium (+serine pulse) or not (-serine
pulse) 1 min before metabolite extraction. Data are presented as mean ± SEM of triplicate wells and are representative of three independent experiments.
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PHGDHi/-SG treatment impairs the general ATF-4 response.
While the effect of PH755 was consistent with a specific inhibi-
tion of PHGDH, analysis of the expression of the serine synthesis
pathway enzymes in response to PH755 treatment revealed an
unexpected response in some of the cell lines. Serine and glycine
starvation has been shown to lead to the activation of ATF-4,
which can mediate a general survival response to metabolic stress.
Importantly, serine starvation leads to an ATF-4 dependent
induction of expression of the SSP enzymes, so contributing to
the ability of the cells to adapt to a reduction in exogenous serine
levels12. We confirmed the importance of this response by
showing that depletion of ATF-4 resulted in an inability of cells to
adapt and grow under serine and glycine starvation (Fig. 5a). As
expected, serine and glycine depletion led to an induction of
expression of all three SSP enzymes in all the cell lines tested,
although this was less robust in MDA-MB-468 cells that
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constitutively overexpress these enzymes (Fig. 5b). However, in
four of the colon cancer lines (HT-29, HCT116, CACO2 and
DLD-1), further treatment of serine and glycine starved cells with
PH755 diminished this increase in SSP enzyme expression
(Fig. 5b), although this was not seen in SW48 cells. A similar
response following serine and glycine starvation and PHGDH
deletion confirmed that this was a response to loss of PHGDH
activity (Fig. 5c). While the decrease in activation of the SSP
enzymes is correlated with the growth inhibition seen following
serine and glycine starvation and PH755 treatment, the failure of
doubly treated cells to induce the SSP enzymes is evident within
4–8 h of serine and glycine starvation (Fig. 5d), suggesting this is a
direct response to PHGDH inhibition rather than an indirect
response to growth arrest. The loss of ability to induce SSP
enzyme expression in response to serine and glycine starvation
was accompanied by a general inability to activate an ATF-4
response, as measured by a lack of induction of the canonical
ATF-4 target, ASNS (Fig. 5b, c). These results suggest that cells
can respond to the combination of serine starvation and SSP
inhibition differently than to either intervention alone.
PHGDHi/-SG treatment inhibits global protein synthesis. To
explore how PHGDH activity affects the ATF-4 response induced
following serine and glycine withdrawal, we examined the level of
activation of the upstream regulators responsible for ATF-4
induction. In response to amino acid starvation, the accumulation
of uncharged tRNA leads to the activation and autopho-
sphorylation of the kinase General Control Non-derepressible 2
(GCN2)33. GCN2 then phosphorylates the eukaryotic transla-
tion initiation factor 2 (eIF2α) at serine 51, leading to a general
downregulation of global protein synthesis but selectively indu-
cing the translation of ATF-434. As expected, serine and glycine
withdrawal induced the phosphorylation of GCN2 and its target
eIF2α in HCT116 and DLD-1 cells (Fig. 6a). Interestingly, this
induction of GCN2 and eIF2α phosphorylation was sustained or
even more pronounced in cells co-treated with PH755 (Fig. 6a),
demonstrating that the lack of ATF-4 upregulation in the double-
treated cells was not due to a lack of activation of its upstream
regulators. ATF-4 protein levels can also be regulated through
ubiquitin-dependent proteasomal degradation35,36. However,
while treatment of cells with the proteasome inhibitor MG-132
led to a strong accumulation of ATF-4 in cells grown in complete
medium, there was no restoration of ATF-4 protein levels or
expression of target gene products ASNS and PSAT in cells grown
in -SG medium plus PH755 (Supplementary Figure 5a). Fur-
thermore, gene expression analysis showed that ATF4 was
induced at the transcriptional level by 24 h after serine and gly-
cine deprivation regardless of the presence of the PHGDH inhi-
bitor (Fig. 6b). These data indicate that the lack of ATF-4
induction in double-treated cells was not due to increased protein
degradation or decreased transcription. As expected, the tran-
scription of ATF-4 target genes encoding ASNS and the SSP
enzymes was strongly up-regulated in serine and glycine starved
cells (Fig. 6b and Supplementary Figure 5b). Interestingly, the
transcription of ATF-4 target genes reflected the extent of ATF-4
induction in the different cell lines grown in -SG medium plus
PH755. DLD-1 cells, which maintained some induction of ATF-4
under these conditions (Fig. 6e), retained the ability to induce
expression of PHGDH, ASNS, PSAT and PSPH (Fig. 6b and
Supplementary Figure 5b) while HT-29 and HCT116 cells, which
showed a more blunted induction of ATF-4 (Fig. 6e) also showed
a more severe defect in the ability to transcriptionally activate
these ATF-4 target genes (Fig. 6b and Supplementary Figure 5b).
We therefore concluded that PH755 treatment did not primarily
affect the transcription of ATF-4 or ATF-4 target genes, but
impacted the subsequent expression of each of these proteins. To
determine whether this reflected a general inhibition of transla-
tion resulting from the dramatic decrease of serine and glycine
availability seen in this condition, we looked at the incorporation
of puromycin, a tyrosyl-tRNA mimetic, into newly synthesised
polypeptides37 in cells grown in CM or -SG medium plus PH755.
Interestingly, while we observed a modest decrease in the amount
of puromycin-labelled peptides in response to serine/glycine
withdrawal, this reduction was much more pronounced in pre-
sence of the PHGDH inhibitor (Fig. 6c). Consistent with a global
inhibition of translation in the double-treated cells, the ability of
proteasome inhibition to drive the accumulation of short-lived
proteins such as c-MYC, HIF1α and p53 was fully blocked in -SG
plus PH755-treated cells (Fig. 6d). As reported under other
conditions that induce a general inhibition of protein synthesis
(such as cycloheximide or puromycin treatment)38, mTORC1 is
hyper-activated in the double-treated cells, as shown by the
accumulation of phosphorylated S6K (Supplementary Figure 5c).
Therefore, it seems that the lack of serine and glycine availability
triggered by the inhibition of both extracellular and intracellular
supplies of these amino acids (Supplementary Figure 1e) inter-
rupts normal translation and prevents the induction of an ATF-4-
mediated protective response. In support of this model, we
observed that the effect of PHGDH inhibition on the ATF-4
response was specific to serine and glycine deprivation, since
treatment with PH755 did not prevent the induction of ATF-4
targets in response to ER stress (Supplementary Figure 5d).
Furthermore, supplementation of the double-treated cells with
formate and glycine – a treatment that restored some level of
serine availability (Fig. 4c) – fully rescued the ATF-4 response
(Fig. 6e). Therefore, in the absence of extracellular serine,
PHGDH activity becomes essential to maintain global protein
synthesis, allowing the induction of a protective ATF-4 response.
Combining -SG diet and PHGDHi is well-tolerated in vivo.
Our in vitro data indicated that the growth inhibitory response to
serine and glycine depletion is greatly augmented by treatment of
cells with the PHGDH inhibitor, prompting us to test the efficacy
of this approach in vivo. Previous reports have shown that our
Fig. 5 Combining PHGDH inhibition with serine/glycine depletion impairs the general ATF-4 response to amino acid starvation. a Growth curves of
HT-29, HCT116 and DLD-1 cells transiently depleted of ATF-4 using short interfering RNA (siRNA) and cultured in -SG medium for 4 days. Data are
presented as mean ± SEM of triplicate cultures and are representative of two independent experiments (*p < 0.05, **p < 0.01, ****p < 0.0001; two-way
ANOVA with Sidak’s post hoc test). b Cells were grown in CM or -SG medium supplemented or not with 10 µM PH755 for 24 h. Western blots show the
expression of the three SSP enzymes PHGDH, PSAT and PSPH (membrane was reprobed with vinculin as a loading control) or the expression of the ATF-4
target ASNS (membrane was reprobed with vinculin as a loading control). Data are representative of at least two independent experiments. c HT-29 and
DLD-1 cells infected with Cas9/PHGDH single guide RNA (sgRNA) were cultured in CM or -SG medium for 24 h. Western blots show expression of
PHGDH, PSAT and PSPH (membrane was reprobed with vinculin as a loading control) or expression of ATF-4 and ASNS (membrane was reprobed with
vinculin as a loading control) in these cells. Data are representative of three independent experiments. d HT-29 and HCT116 cells were grown in CM or -SG
medium supplemented or not with 10 µM PH755 for 4 h, 8 h, 12 h, 16 h and 24 h. Western blots show SSP enzymes expression in these cells. Each
membrane was reprobed with vinculin as a loading control. Data are representative of two independent experiments.
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serine- and glycine-free (-SG) diet can lead to a modest drop in
body weight in mice7 and we showed inhibition of both normal
and cancer intestinal organoid growth in response to double
treatment in vitro (Supplementary Figure 2). To assess the tol-
erability of dietary serine/glycine limitation with PH755 treat-
ment, we examined the response to the various treatments in a
cohort of tumour-free immunocompetent C57BL/6J mice. As
seen previously7, mice moved to the -SG diet showed a slight
drop in weight that stabilised over the course of the study
(Supplementary Figure 6a). Treatment with PH755 alone did not
result in any detectable adverse response in these mice, which did
not lose body weight compared to control mice (Supplementary
Figure 6a). However, mice co-treated with PH755 and the -SG
diet showed greater weight loss compared to either treatment
alone (Supplementary Figure 6a), despite remaining active and
appearing healthy. The weight loss was highly responsive to the
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dose of PH755, and modulation of the dose (from 75 to 50 mg/
kg) was successful in limiting weight loss to <20% over the course
of the study (Supplementary Figure 6a). Serine is important in
brain development and function and PHGDH deficiency in
humans can lead to neurological defects such as microcephaly,
psychomotor retardation and seizures39. We therefore assessed
the impact of -SG diet and PHGDH inhibitor treatment on the
brain morphology of a cohort of C57BL/6J mice after 20 days of
treatment. Microscopic examination of coronal sections from the
brains of the four groups of mice at the level of the pyriform
cortex, caudal diencephalon, caudal mesencephalon and rostral
cerebellum did not reveal any histopathological lesions in any of
the sections examined. Indeed, Haematoxylin & eosin stained
sections exhibit normal histological features with no evidence of
degeneration, necrosis or inflammation (Supplementary Figure
6b, c). Furthermore, the brain weight remained unchanged in all
groups of mice (Supplementary Figure 6b). We also looked for
other signs of toxicity of the double treatment in these normal
mice. Measurement of plasma AST and ALT activity at end point
did not reveal any significant elevation of these markers of liver
toxicity in the group of mice treated with -SG diet and PH755
(Supplementary Figure 6d), while plasma urea and creatinine
levels remained normal in the double-treated mice, suggesting
that there was no kidney damage (Supplementary Figure 6e).
The only clear deleterious effect of the double treatment in
mice was weight loss, and our in vitro work using normal mice
organoids derived from small intestine revealed that the
combination treatment altered their ability to grow (Supplemen-
tary Figure 2b). While serine and glycine starvation or PHGDH
inhibition alone had no detectable effect on gut morphology, we
did note a significant decrease in the length of intestinal villi in
animals co-treated with the -SG diet and PH755 (Supplementary
Figure 6f), consistent with the greater weight loss seen in these
mice. However, these mice showed no clear defect in crypt
proliferation – assessed by Ki-67 staining – (Supplementary
Figure 6g), suggestive of relatively unperturbed crypt home-
ostasis. These results are consistent with the observation that
reduction in the dose of PHGDH inhibitor stops further weight
loss and suggest that short-term combination treatment does not
cause long-term damage.
Combining -SG diet and PHGDHi impedes tumour growth
in vivo. To explore the antitumor efficacy of the combination
therapy, we used xenograft models with two of the colon cancer
cell lines that had been tested in vitro, DLD-1 and HCT116.
Following subcutaneous injection of cells, mice were transferred
to a -SG or control diet when tumours started to become evident
and treated with PH755 2–4 days later. As seen in the non-
tumour-bearing mice, the double-treated DLD-1 tumour-bearing
mice showed more weight loss compared to either treatment
alone but a careful modulation of the dose of PH755 used in
association with the -SG diet was able to limit the weight loss in
these mice to <20% over the course of the experiment (Supple-
mentary Figure 7a). This enhanced weight loss was avoided by
increasing the time between diet change and PH755 treatment
from 2 to 4 days in the HCT116 experiment (Supplementary
Figure 7a, b). Analysis of the circulating amino acid levels at the
end point of the studies confirmed previous observations that the
-SG diet resulted in a decrease in plasma serine and glycine levels
(Fig. 7a and Supplementary Figure 7c). While treatment of mice
with PH755 had a more modest effect on circulating serine and
glycine, a combination of the -SG diet and PH755 most effectively
lowered plasma serine and glycine levels reaching absolute con-
centration as low as 58 μM serine (versus 267.7 μM in control
mice and 99.9 μM in mice fed a -SG diet only) and 102.3 μM
glycine (versus 367.6 μM in control mice and 143.6 μM in mice
fed a -SG diet only; Fig. 7a and Supplementary Figure 7c). The
growth of tumours arising from DLD-1 cells was not affected by
dietary intervention or PH755 treatment alone (Fig. 7b), con-
sistent with the lack of effect of either of these treatments on the
proliferation of these cells in vitro (Fig. 1b). However, a combi-
nation of diet and PH755 strongly inhibited the growth of these
tumours (Fig. 7b). The growth of HCT116 xenograft tumours was
somewhat sensitive to dietary serine and glycine restriction (as
previously shown7) and also showed a trend to a decrease in mice
treated with PH755 (Fig. 7c), consistent with a previous report
showing an effect of PH755 on HCT116 tumour growth24.
However, the combination treatment of diet and PH755 almost
completely blocked the growth of these tumours (Fig. 7c).
Interestingly, the strong growth inhibition observed in the
double-treated tumours was accompanied by an increased cell
death, as reflected by an increased number of active caspase-3
positive cells in DLD-1 tumours treated with the combination
therapy (Fig. 7d). Analysis of the serine and glycine levels in the
tumours from these mice mirrored the results from the plasma,
showing either PH755 treatment or -SG diet lowered intra-
tumoral serine and glycine levels (Fig. 7e and Supplementary
Figure 7d), although in each case the -SG diet was more effective
in lowering intra-tumoral serine and glycine levels that treatment
with the PHGDH inhibitor. HCT116 tumours showed a modest
further drop in serine and glycine in the combination diet and
drug treated mice (Supplementary Figure 7d) but in DLD-1
tumours, the reduction in serine in response to the -SG diet was
not further affected by additional PH755 treatment (Fig. 7e).
Nevertheless, a further reduction in intra-tumoral glycine in the
double-treated mice suggests that flux through the SSP is lower in
the double-treated tumours and that the maintenance of the low
Fig. 6 Combining PHGDH inhibition with serine/glycine depletion inhibits global protein synthesis. a Cells were grown in CM or -SG medium
supplemented or not with 10 µM PH755 for 24 h. Western blots show Phospho-GCN2 (Thr899), GCN2, Phospho-eIF2α (Ser51) and eIF2α. Membranes
were reprobed with vinculin as a loading control. Data are representative of two independent experiments. b Cells were grown in CM or -SG medium
supplemented or not with 10 µM PH755 for 6 h or 24 h. Relative gene expression of ATF4 and PHGDH were measured by qPCR and normalised to the cells
grown in CM for 6 h. Data are presented as mean ± SEM of triplicate cultures and are representative of two independent experiments (*p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001; one-way ANOVA with Tukey’s post hoc test). c Cells were grown in CM or -SG medium supplemented or not with 10 µM
PH755 for 24 h. Puromycin (90 µM) was added in culture medium 10min before harvesting the cells. When indicated, cells were treated with 10 µg/mL
cycloheximide (CHX), a well-known protein synthesis inhibitor, 5 h before harvesting the cells. Western blots show puromycylated peptides. Membrane
was reprobed with vinculin as a loading control. Data are representative of two independent experiments. d Cells were grown in CM or -SG medium
supplemented or not with 10 µM PH755 for 24 h. When indicated, cells were treated with 10 µMMG-132, a proteasome inhibitor, 6 h before harvesting the
cells. Western blots show the expression of c-MYC, HIF1α and p53. Membrane was reprobed with vinculin as a loading control. Data are representative of
three independent experiments. e Cells were grown in CM, -SG medium or -SG medium +10 µM PH755 supplemented or not with 1 mM sodium formate
plus 0.4 mM glycine (For/Gly). Western blot shows the expression of the three SSP enzymes PHGDH, PSAT and PSPH or the expression of ATF-4 and its
canonical target ASNS after a 24 h incubation in these medium. Membrane was reprobed with vinculin as a loading control. Data are representative of two
independent experiments.
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steady state levels of serine may reflect the decrease in growth
(and serine consumption) under these conditions (Fig. 7e).
Our in vitro data showed that complete inhibition of serine
availability through serine starvation and PHGDH inhibition led
to defects in one-carbon metabolism and a global inhibition of
translation that correlated with a failure to induce an ATF-4
response. To examine these responses to dietary serine/glycine
starvation and PHGDH inhibition in vivo, we first examined
purine levels in the tumours. As noted in vitro (Supplementary
Figure 3c), we did not see any difference in total ATP or GTP
levels in tumours from double-treated mice (Supplementary
Figure 7e), likely reflecting the decreased proliferation of the
double-treated tumour cells. In the methionine cycle, the
regeneration of SAM from SAH requires one-carbon units.
Interestingly, we noted a clear reduction in the SAM/SAH ratio in
tumours from -SG diet mice, which was further reduced in mice
on -SG diet plus PH755 (Fig. 7f). These results are consistent with
a reduction in one-carbon availability in mice on a -SG diet that is
exacerbated in double-treated mice.
To examine the ATF-4 response, we measured the expression
of the two ATF-4 targets, PHGDH and PSAT1, in DLD-1
tumours (Supplementary Figure 7f, g). Immunohistochemistry
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analysis of these tumours revealed that feeding mice with a -SG
diet led to a clear induction of PSAT1 – and to a lesser extent
PHGDH – in tumours, indicating the induction of an ATF-4
response in vivo. By contrast, treating mice with the PHGDH
inhibitor alone did not result in any change in PHGDH or PSAT1
expression, suggesting that only dietary restriction of serine and
glycine was effective to deplete serine and glycine intra-tumoral
levels enough to lead to an ATF-4 response in vivo. Interestingly,
the induction of PSAT1 and PHGDH was equivalent or even
more pronounced in the double-treated tumours compared to the
tumours from mice fed a -SG diet only, showing that, in vivo, the
combination treatment did not reduce available serine sufficiently
to compromise the ability of tumour cells to induce an ATF-4
response (Supplementary Figure 7f, g). Taken together, these data
show that the inhibition of tumour growth correlate with defects
in serine metabolism, rather than inhibition of translation.
Discussion
This study has explored the efficacy of a combination of serine/
glycine depletion with PHGDH inhibition to inhibit cancer cell
growth. Our analyses of cell lines and organoids showed that
when used at a concentration that effectively inhibited de novo
serine synthesis, treatment with PH755 alone had no impact on
cell growth. These data suggest that all the cell lines used were
able to import exogenous serine efficiently enough to maintain
proliferation. These results are in contrast to previously reported
PHGDH inhibitors that inhibited growth of PHGDH expressing
cells in the presence of extracellular serine and glycine26–28. These
previously published compounds showed weaker activity than
PH755, and in some cases exhibited some additional activities,
such as electron transport chain inhibition26. Differences in the
mode of action of the inhibitors (PH755 is an NAD+ competitive
inhibitor while others function by disrupting the PHGDH tetra-
mer27 or as non-competitive inhibitors26,28) or in the selectivity
of these compounds at the doses used in cell growth assays may
account for the different responses in the presence of serine.
Previous studies have also shown that cell lines like MDA-MB-
468, which express high levels of PHGDH and have activated SSP,
are sensitive to sh-RNA mediated depletion of PHGDH,
regardless of the presence of serine in the medium14,15, indicating
a difference between loss and inhibition of PHGDH. It has been
suggested that activation of the SSP is important not only for
serine production, but can also contribute to the generation of α-
ketoglutarate (through the PSAT1 reaction)14 or the redox bal-
ance in the cell (as PHGDH consumes NAD+)40. However,
depletion and inhibition of PHGDH is unlikely to affect these two
processes differently. It is possible that the PHGDH protein has
functions additional to supporting the SSP and that this activity is
maintained in the presence of the PHGDH inhibitor. Further
analysis will be required to address this point.
Using xenograft models of intestinal cancer, we have provided
a proof of concept that limiting the availability of serine and
glycine to tumours by targeting the exogenous and endogenous
supply can have therapeutic benefit. While we did not see a clear
beneficial effect of PH755 treatment alone compared to the -SG
diet, the combination showed augmented therapeutic efficacy.
These observations show some parallels to other approaches
aimed at limiting the supply of NEAAs to cancers that are already
in clinical use, such as treatment of patients with ASS1 deficient
cancers (so blocking the de novo pathway of arginine synthesis)
with ADI-PEG20, to degrade circulating arginine41. Consistent
with a recent study showing no overt toxicity associated with
depletion of PHGDH in adult mice (sparing the brain)42, mice
fed on a normal diet tolerated treatment with PH755 well,
showing that in the presence of exogenous serine, inhibition of
the SSP was not detrimental to health. Similarly, PH755 did not
affect the growth of cells in serine and glycine containing med-
ium. However, we did not assess long-term treatment with the
inhibitor, and studies showing that serine synthesis through the
activity of PHGDH is important for the maintenance of nucleo-
tide levels43 or haem production in endothelial cells44 suggests
that there may be some longer term on-target effects that would
need careful monitoring. In particular, in mice and humans,
PHGDH deficiency leads to severe neurological defects, although
PHGDH heterozygous mice are normal, despite a reduction in
brain serine levels45,46. The lack of obvious neurological symp-
toms following PH755 treatment possibly reflects an incomplete
inhibition of the SSP or a lower requirement for PHGDH in the
adult brain. Even the combination of -SG diet and PH755
treatment – which effectively lowered circulating serine levels –
did not lead to overt morphological changes in the brain,
although more detailed behavioural analysis would be required to
rule out any effect on brain function. More generally, the mice on
the combination treatment appeared active and healthy. There
was no evidence of liver or kidney toxicity although a reduction in
intestinal villi length correlated with the weight loss observed in
these mice. However, the intestinal crypts appeared to be unaf-
fected, consistent with the stabilisation of weight following a
reduction in PH755 dosing, even when left on the -SG diet. It
remains possible that long-term serine and glycine limitation will
result in unwanted toxicities. Indeed, a recent study showing
long-term dietary serine and glycine starvation leads to retinal
defects in mice47 suggests that shorter term application of these
Fig. 7 Dietary restriction of serine and glycine and PHGDH inhibition synergizes to deplete circulating and intratumor levels of these amino acids to
inhibit tumour growth in xenograft models of colorectal cancer. a Serine and glycine levels in plasma from DLD-1 tumour-bearing mice fed a control diet
(CTR) or an equivalent diet lacking serine and glycine (-SG) and treated with vehicle (Veh) or PH755. CTR+Veh: n= 10; CTR+ PH755: n= 10; -SG+
Veh: n= 10; -SG+ PH755: n= 9. Data are presented as mean ± SEM. (**p < 0.01, ****p < 0.0001, unpaired two-sided Student’s t test). b Mice
subcutaneously injected with DLD-1 cells were moved to CTR or -SG diet 2 days after tumour cell injection. Two days after diet change, mice were dosed
with vehicle or PH755 once daily for 20 days. The starting dosage of PH755 (100mg/kg for 7 days) was lowered to 50mg/kg (for 6 days) and increased
to 75mg/kg (for 7 days). Tumour volumes are presented as mean ± SEM. CTR+Veh: n= 10; CTR+ PH755: n= 10; −SG+Veh: n= 10; -SG+ PH755:
n= 9. (ns: no significance, **p < 0.01; two-way ANOVA plus Tukey’s post hoc test). c Mice subcutaneously injected with HCT116 cells were moved to CTR
or -SG diet ten days after tumour cell injection. Four days after diet change, mice were dosed with vehicle or PH755 once daily for 11 days. The starting
dosage of PH755 (100mg/kg for 3 days) was lowered to 50mg/kg (for 8 days). Tumour volumes are presented as mean ± SEM. CTR+Veh: n= 8; CTR
+ PH755: n= 7; −SG+Veh: n= 8; −SG+ PH755: n= 7. (ns: no significance, *p < 0.05; two-way ANOVA plus Tukey’s post hoc test). d Representative
immunohistochemistry pictures and quantification of active Caspase-3 positive cells in DLD-1 tumours harvested at end-points from mice fed a CTR or -SG
diet and treated with vehicle or PH755. CTR+Veh: n= 9; CTR+ PH755: n= 9; -SG+Veh: n= 10; -SG+ PH755: n= 8. Data are presented as mean ±
SEM. (*p < 0.05; unpaired two-sided Student’s t test with Welch’s correction). Scale bar represents 50 μm. e, f Serine, glycine, SAM/SAH ratios in tumour
lysates. Peak area was normalised to total ion count. e CTR+Veh: n= 10; CTR+ PH755: n= 10; -SG+Veh: n= 10; -SG+ PH755: n= 9. f CTR+Veh: n=
9; CTR+ PH755: n= 9; -SG+Veh: n= 10; -SG+ PH755: n= 8 (*p < 0.05, **p < 0.01; unpaired two-sided Student’s t test with Welch’s correction applied
when necessary). (n= number of mice).
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approaches for cancer therapy are likely to be required. However,
it is encouraging that we were able to maintain the combined
drug and diet treatment for long enough to detect a therapeutic
benefit without any acute adverse effects. Further studies to
establish the optimal effective dose and dosing regime, to balance
modulation of serine availability to the tumour with weight loss,
will likely lead to even better responses.
The inhibition of tumour growth in response to -SG diet plus
PHGDH inhibition shown here are consistent with a recent study
showing that depletion of PSAT1 (the second step in the SSP) in
liver cancers reduced tumour growth only in a -SG diet25. In
vitro, we show that removal of extracellular serine and glycine
availability combined with inhibition of PHGDH effectively
depleted intracellular serine levels and blocked glutathione and
nucleotide synthesis in cultured cells, consistent with defects in
one-carbon metabolism. Inactivation of mTORC1 in response to
amino acid starvation results in a general inhibition of translation
and increased autophagy48. This response is often coupled with
the selective activation of ATF-4 translation, which mediates a
protective response including the upregulation of expression of
amino acid transporters and de novo synthesis pathways35,49.
While we also saw induction of an ATF-4 response in cells
starved of serine and glycine, we found that the dramatic drop in
serine availability seen in response to both serine and glycine
starvation and PHGDH inhibition in vitro led to a more pro-
found inhibition of translation that prevented the induction of the
protective ATF-4 response. This defect was reflected in the almost
complete growth inhibition seen in cells that were grown in both
adherent 2D conditions or as organoids following serine and
glycine starvation plus PHGDH inhibition. While we were able to
find evidence of a defect in one-carbon availability in tumours
from double-treated mice, we did not see a loss of an ATF-4
response. It remains possible that synthesis of other proteins may
be retarded in double-treated mice, but the maintenance of the
ATF-4 response likely reflects the retention of some serine
availability to the tumour cell (potentially from surrounding
stromal cells). These results highlight that caution needs to be
applied to translating in vitro results – where complete blocks to
metabolic pathways can be achieved – to in vivo situations –
where these pathways may only be partially inhibited. However,
the retention of an ATF-4 response may explain why the com-
bination therapy – which strongly inhibited normal cell growth
in vitro – was not highly toxic to normal cells in mice.
While our work supports a role for defects in one-carbon
metabolism in the success of the combination treatment, other
responses to lack of serine availability may also contribute. For
example, a recent study has shown that inhibition of tumour
growth in -SG fed mice may reflects the production of toxic
deoxysphingolipids24. While the combination of PH755 with a
serine and glycine depleted diet could be beneficial in many
cancer types, tumours arising in an environment naturally low in
serine could benefit from PH755 treatment without the require-
ment for additional dietary intervention23. As shown recently,
treatment with PH755 was effective in limiting serine synthesis
and tumour growth of metastases in the brain, where environ-
mental serine and glycine levels are low31. Furthermore, tumours
carrying other genetic alterations that lead to resistance to dietary
serine depletion, such as p53 or KRAS mutations, may be sen-
sitive to the combination therapy described here. Stratification of
tumours to account for intrinsic vulnerability to serine limitation
and extrinsic limitation of serine levels is likely to further improve
the efficacy of this approach.
Methods
Cell culture. All the human cell lines used in this study were obtained from the
Crick Cell Services. All cell lines underwent routine quality control, which included
mycoplasma detection, STR profiling and species identification for validation. Cells
were cultured at 37 °C in a humidified atmosphere of 5% CO2. HT-29, SW48,
SW480, SW620, CACO2, HCT116, RKO, VACO5 and MDA-MB-468 cells were
cultured in DMEM (Gibco, 41966) supplemented with 10% FBS; DLD-1, HCT-15
and SW1417 cells were cultured in RPMI 1640 medium (Gibco, 21875) supple-
mented with 10% FBS and LoVo and CL-34 cells were cultured in DMEM/F12
(Gibco, 11320) supplemented with 10% FBS.
Serine and glycine deprivation. For all serine and glycine-deprivation experiments,
cells were cultured in MEM (Gibco, 21090) supplemented with 10% dialysed FBS
(Hyclone, Thermo Scientific), 1% penicillin–streptomycin, D-glucose (5 mM),
sodium pyruvate (65 µM), 1X MEM vitamin solution (Gibco, 11120), L-Glutamine
(2 mM), L-Proline (0.15 mM), L-Alanine (0.15 mM), L-Aspartic acid (0.15 mM),
L-Glutamic acid (0.15 mM) and L-Asparagine (0.34 mM) (-SG media). The com-
plete medium (CM) corresponds to the previously described medium supple-
mented with 0.4 mM L-Serine and 0.4 mM L-Glycine.
Growth curves. Cells (2 × 104 to 3 × 104 cells/well depending on the cell lines) were
plated in 24-well plates in their regular medium. The next day, after being washed
with PBS, cells were transferred to -SG medium or CM and treated with 10 µM
PH755 (RAZE Therapeutics) diluted in DMSO or DMSO alone. For the counting
step, cells were trypsinized, suspended in PBS-EDTA and counted with a CASY
Model TT Cell Counter (Innovatis, Roche Applied Science). Relative cell number at
each time point was calculated based on the number of cells measured before the
medium change. For the growth curve experiment with formate and glycine sup-
plementation, HT-29, HCT116 and DLD-1 cells were seeded in 24-well plates (2 ×
104 cells/well). Sodium formate (Fluka Analytical, 71540) (1 mM) and/or glycine
(0.4 mM) were diluted in -SG medium+ 10 µM PH755 and medium was refreshed
every two days.
Organoids. Crypts were isolated from adenomatous small intestine tissue derived
from Vil1-creER;Apcfl/fl and Vil1-creER;Apcfl/fl;KrasG12D/+ mice as previously
described17. The generation of the Apc5 organoid bearing an Apc truncating
mutation using CRISPR/Cas9 technology and isolation of normal organoids
derived from the proximal part of healthy small intestine from Villin-CreERT2
mouse were performed as previously described50–52. The generation of the four
patient-derived colorectal organoids used in this study has been described pre-
viously32. Cancer organoids from mice were cultured in tumour organoid medium
(CM) composed of Advanced DMEM/F12 (Gibco, 12634) supplemented with 1%
penicillin–streptomycin solution, 0.1% BSA, 2 mM L-glutamine, 10 mM Hepes, 50
ng/mL EGF (PeproTech AF-100-15), 100 ng/mL Noggin (PeproTech 250-38), 500
ng/mL Spondin (PeproTech 120-38), 1X N-2 Supplement (ThermoFisher
17502048) and 1X B-27 Supplement (ThermoFisher 17504044). The -SG medium
corresponds to the previously described medium without serine and glycine.
Normal organoids from mice were grown in normal organoid medium, a mod-
ification of tumour organoid medium that was supplemented with 100 ng/mL
Wnt-3a (R&D systems, 5036-WN), 1 mM N-Acetyl-L-cysteine (Sigma, A7250), 10
μM Y-27632 (Sigma, Y0503) and 4 mM Nicotinamide (Sigma, N0636). Human
organoids were grown in human organoid medium, a second modification of
tumour organoid medium that was supplemented with 10 nM FGF-basic (Pepro-
Tech, 100-18B), 100 ng/mL Wnt-3a (R&D systems, 5036-WN), 1 μM Pros-
taglandin E2 (Tocris, 2296), 4 mM Nicotinamide (Sigma, N0636), 20 ng/mL HGF
(PeproTech, 100-39), 10 nM FGF-10 (PeproTech, 100-26), 10 nM Gastrin I (Sigma,
G9145), 10 μM Y-27632 (Sigma, Y0503), 0.5 μM A 83-01 (Tocris, 2939) and 5 μM
SB 202190 (Sigma, S7067). For the splitting step, organoids were harvested through
mechanical pipetting using TrypLE (Gibco, A12177-01), incubated for 10 min at
37 °C, diluted three times in volume in ice-cold 1X HBSS (Gibco, 14175-053) and
spun down at 270×g for 5 min at 4 °C. Pellet was then resuspended in growth factor
reduced Matrigel (Corning, 356231) and plated in 24-well plates. Matrigel was then
incubated for 15 min at 37 °C and 1 mL of the CM described above was added. The
next day, organoids were washed with PBS and the medium was replaced with CM
or -SG medium supplemented or not with 10 µM PH755 and allowed to grow.
Pictures were regularly taken with a light microscope (Zeiss, Axiovert 40 CFL)
using Infinity Capture (version 6.5.4) and organoid diameter was measured using
ImageJ software.
Generation of PHGDH KO cells. pLentiCRISPRv2 vector containing the following
guide RNA: TGGACGAAGGCGCCCTGCTC was purchased from Genscript to
target PHGDH. HEK293T cells were transfected with this lentiviral plasmid
together with psPAX2 (Addgene, 12260) and VSV.G (Addgene, 14888) using jet-
PRIME reagent (Polyplus transfection). After 24 h incubation, medium was
changed and 48 h later, the viral particle containing-medium was filtered (0.45
mm) and mixed with polybrene (4 µg/ml, Sigma-Aldrich). The medium containing
lentiviruses was incubated with the target cells for 24 h. HT-29 and DLD-1 cells
were then selected with puromycin (Sigma-Aldrich) for 3 weeks and analysed for
loss of PHGDH expression.
ATF-4 siRNA transfection. The siRNA used to downregulate human ATF-4 and
the non-targeting siRNA control were purchased from Dharmacon (siGENOME
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SMART pool siRNA). Cells were transfected with siRNA using Lullaby transfection
reagent (OZ Biosciences) following the manufacturer’s instructions.
BrdU/7-AAD staining. HCT116 and DLD-1 cells were grown for 48 h in -SG
medium or CM and treated with 10 μM PH755 diluted in DMSO or DMSO alone.
To determine the percentage of bromodeoxyuridine (BrdU) positive cells, 10 μM
BrdU was then added to culture media for an additional 5 h while for cell cycle
analysis, 10 μM BrdU was added for only 30 min. Cells were then harvested, fixed
and stained with APC anti-BrdU antibody (and 7-AAD for cell cycle analysis)
using the APC BrdU Flow kit (BD Pharmingen, Cat no: 552598) following the
manufacturer’s instructions. Fluorescence was acquired with FACSdiva on a For-
tessa flow Cytometer and the analysis performed using FlowJo (version 10.5.2).
Western blot. Protein lysates were processed in RIPA-buffer (Millipore) supple-
mented with phosphatase inhibitor cocktail (Thermo Fisher Scientific) and com-
plete protease inhibitors (Roche). Lysates were separated using precast NuPAGE
4–12% Bis-Tris Protein gels (Invitrogen) and transferred to nitrocellulose mem-
branes. Following incubation with primary antibodies, appropriate secondary
antibodies were used to detect the proteins. Western blots were scanned using the
LI-COR Odyssey infrared scanner (imaged using LI-COR Image Studio Lite soft-
ware version 5.2.5) or visualised using ECL chemiluminescence detection kits
(Pierce). Primary antibodies used were as follows: PHGDH (13428), ATF-4
(11815), Phospho-eIF2α (Ser51) (3398), Phospho-p70S6 kinase (Thr389) (9234),
p70S6 kinase (9202), c-Myc (5605), HIF1α (14179), Caspase-3 (9662), Cleaved
Caspase-3 (Asp175) (9661), beta-Actin (4970) from Cell Signaling Technology;
GCN2 (sc-374609), eIF2α (sc-133132), p53 (sc-126), Vinculin (sc-73614) from
Santa Cruz Biotechnology; PSAT (ab96136), PSPH (ab96414), Phospho-GCN2
(Thr899) (ab75836) from Abcam; ASNS (HPA029318) from Atlas Antibodies;
Puromycin (MABE343) from Sigma-Aldrich. All primary antibodies were diluted
at 1:1000 dilution except puromycin antibody (1:20,000). Uncropped and unpro-
cessed scans of the most important blots are supplied in the Source Data file.
Protein synthesis and degradation. Cells were grown for 24 h in -SG medium or
CM and treated with 10 μM PH755 diluted in DMSO or DMSO alone. To evaluate
protein synthesis, puromycin (final concentration: 90 μM) was added to each well
10 min prior harvesting the cells for western blot analysis, except in the negative
control well. Where indicated, cells grown in CM medium were treated with
cycloheximide (10 μg/mL) for the last 5 h providing a control for translation
inhibition. Incorporation of puromycin into newly synthesised proteins was
assessed by western blot using an anti-puromycin antibody (Sigma-Aldrich,
MABE343). To assess the accumulation of short-lived proteins in response to
proteasome inhibition, cells grown in -SG medium or CM plus or minus 10 μM
PH755 for 24 h were treated for the last 6 h with the proteasome inhibitor MG-132
(10 μM) before harvesting the cells for western blot analysis.
qPCR. HT-29, HCT116 and DLD-1 cells were grown for 6 h or 24 h in -SG
medium or CM and treated with 10 μM PH755 diluted in DMSO or DMSO alone.
Total RNA was extracted using RNeasy Mini kit (Qiagen, Cat No.: 74104) per-
forming on-column digestion of DNA (Qiagen, RNase-Free DNase Set, Cat No.:
79254) and reverse transcribed using the High-Capacity cDNA Reverse Tran-
scription kit (Thermofisher, Cat No.: 4368814) according to the manufacturer’s
instructions. qPCR was performed using PrimeTime Gene Expression Master Mix
(IDT, Cat No: 1055771) with the primers listed in Supplementary Table 1. The
QuantStudio 7 Flex Real-Time PCR System (software v1.3) was used for all reac-
tions. Gene expression was normalised to ACTB (β-actin) housekeeper gene,
analysed according to Pfaffl method53 and expressed as relative units compared to
the cells grown in CM for 6 h.
Liquid chromatography–mass spectrometry. HT-29 cells (2.4 × 105), HCT116
cells (1.8 × 105), DLD-1 cells (1.8 × 105) and MDA-MB-468 cells (2.4 × 105) were
plated in six-well plates in their regular medium. Duplicate plates were used for cell
counting to normalise LC-MS analysis based on cell number. After 16 h, cells were
washed with PBS and transferred to CM or -SG medium supplemented or not with
10 µM PH755 for 24 h. In all, 6 h before metabolite extraction, medium was
replaced with CM or -SG medium ±10 µM PH755 with glucose substituted for 10
mM U-[13C]-glucose (Cambridge Isotopes). For short-term experiments, cells were
moved to the previously described medium with glucose substituted for 10 mM U-
[13C]-glucose for only 3 h or 6 h before metabolite extraction. For measurement of
glycine conversion into serine during rescue experiment, cells were grown for 24 h
in -SG medium supplemented with 10 µM PH755, 1 mM sodium formate and 0.4
mM glycine. This medium was then replaced with matched medium with glycine
substituted for 0.4 mM 13C215N1-glycine for 1 h before metabolite extraction. For
half of the samples, a pulse of 1 mM unlabelled serine was added to the medium 1
min before metabolite extraction to allow labelled serine to accumulate. Cells were
then washed with PBS and metabolites were extracted using ice-cold extraction
buffer composed of methanol, acetonitrile and H2O in the following ratio 50:30:20.
For LC-MS analysis on tumour samples, tissue was homogenised (20–40 mg tissue/
mL of the previously described extraction buffer) using the Precellys 24 homo-
genizer (Bertin Instruments). Samples were spun (16,000×g/10 min/0 °C) and the
supernatant collected to be centrifuged again (16,000×g/10 min/0 °C). Supernatant
were then collected for LC-MS analysis. For LC-MS analysis on mice plasma,
plasma was diluted 20–50 fold with the same extraction buffer, vortexed for 30 s
and centrifuged (16,000×g/10 min/0 °C). Supernatant were then collected for
analysis. Absolute levels of serine and glycine in plasma was determined using 8-
point calibration curves (from 2.5 to 800 µM) with 13C315N1-serine and 13C215N1-
glycine diluted in plasma. LC-MS analysis was performed as previously described9.
Data were recorded using Xcalibur 4.0.27.19 software (Thermo Scientific). Ver-
ification of qualitative peak assignments was done with Qual Browser from Xca-
libur 4.0.27.19 and metabolite peak integration was performed using
TraceFinder 4.1.
In vivo experiments. All animal studies were conducted in compliance with UK
Home Office approved project licences (Animals (Scientific Procedures) Act 1986
and the EU Directive 2010). Animal experiments were subject to ethical review by
the Francis Crick Animal Welfare and Ethical Review Body and carried out under
UK Home Office project license P319AE968 or by the CRUK Beatson Institute
(reviewed and approved by the University of Glasgow and UK Home Office) and
carried out under UK Home Office project license 70/8645. Mice (3–5 per cage)
were allowed access to food and water ad libitum and were kept in a 12-h day/night
cycle starting at 7:00 until 19:00. Rooms were kept at 21 °C at 55% humidity. Mice
were allowed to acclimatise for at least 1 week prior to the experiment. They were
then randomly assigned to experimental groups. The experimental diets used in
this study (control diet and -SG diet) were previously described as “Diet 1-Control”
and “Diet 1-SG-free”17. Briefly, the control diet contains all essential amino acids as
well as serine, glycine, glutamine, arginine, cystine and tyrosine. The -SG diet is the
same as the control diet but is deprived of serine and glycine, which are com-
pensated by a proportionally increased level of the other amino acids to reach the
same total amino acid content.
Xenograft experiments. CD-1 female nude mice (obtained from Charles River,
7–9 weeks old) received unilateral subcutaneous injections of 100 µl of HCT116
cells (2 × 106 cells) or 100 µl of DLD-1 cells (4 × 106 cells) suspended in PBS. Mice
were placed on experimental diets (control or -SG) 10 days (for HCT116 xenograft
experiment) or 2 days (for DLD-1 xenograft experiment) after tumour injections.
In all, 4 days (for HCT116 xenograft experiment) or 2 days (for DLD-1 xenograft
experiment) after the diet change, mice were treated either with vehicle (0.5%
methylcellulose (Sigma, H7509), 0.5% Tween-80 (Sigma, P8192)) or PH755
(obtained from Raze Therapeutics) prepared in vehicle once daily by oral gavage.
The starting dosage of PH755 was 100 mg/kg and was subsequently lowered to 75
mg/kg or 50 mg/kg as indicated in the figure legends. Subcutaneous growth was
measured two to three times a week by caliper and the following formula: length ×
width2/2 was used to calculate tumour volume.
C57BL/6J experiment. C57BL/6J male mice (obtained from Charles River, 14 weeks
old) were placed on experimental diets (control or -SG) 2 days before starting the
treatment with PH755 or its vehicle. Mice were treated once daily by oral gavage
with PH755 or its vehicle for 20 days. The starting dosage of PH755 was 75 mg/kg
and was subsequently lowered to 50 mg/kg to maintain weigh loss below 20% of the
initial body weight.
Immunohistochemistry. All tissues were fixed in 10% neutral buffered formalin
and were embedded in paraffin. For PHGDH and PSAT1 staining, the slides were
de-paraffinised in xylene and rehydrated using a series of graded industrial
methylated spirits solutions and distilled water. Antigen retrieval was performed
for 23 min in the microwave using pH 6 0.1 M citrate buffer. Endogenous perox-
idase blocking was performed using 1.6% H2O2 for 10 min at room temperature
and protein blocking was performed using 2.5% Normal Horse Serum (MP-7401,
Vector) overnight at 4 °C. Primary antibody was diluted at 1:1000 for PHGDH
antibody (HPA021241, Sigma-Aldrich) and at 1:500 for PSAT1 antibody (PA5-
22124, Thermofisher) in 1% BSA, and incubated for 1 h at room temperature. HRP
Horse Anti-Rabbit IgG Polymer (MP-7401, Vector) was incubated for 30 min at
room temperature. 3,3-diaminobenzidine (DAB) chromogen (SK-4100, Vector)
was incubated for 10 min at room temperature. The slides were counterstained
with Harris Heamatoxilin, dehydrated, cleared and mounted in a Sakura Tissue-
Tek Prisma® auto stainer. For PHGDH and PSAT1 staining intensity quantifica-
tion, a minimum of three fields per tumour were quantified as described in Crowe
et al.54 with ImageJ. Active Caspase-3 immunohistochemistry was performed on
the Discovery Ultra Ventana platform (from Roche). Antigen retrieval was
obtained with Cell Conditioning 1 (CC1) from Ventana Medical Systems. Primary
antibody (AF835, R&D Systems) was diluted at 1:1250 and incubated for 60 min.
For Active Caspase-3 staining, a minimum of three fields per tumour were
quantified with the positive cell detection algorithm from QuPath (version 0.1.2).
All slides were scanned with the ZEISS Axio Scan.Z1 slide scanner and images were
generated through ZEISS ZEN 2.6 (blue edition) software. For gut rolls, immu-
nohistochemistry was performed on Bond Rx Autostainer from Leica Biosystems
using Leica Bond Intense R staining kit. Slides were de-paraffinised with Bond
Dewax at 72 °C for 30 min and antigen retrieval was achieved with ER2 at 100 °C
for 20 min. Primary antibody (Ki67 SP6, ab16667, Abcam) was diluted at 1/100
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and incubated for 35 min. For villus length measurement, villi from the same area
of the small intestine (at least 15 per mouse) were measured from the crypt/villus
junction to the villus tip, using ImageJ.
Brain sampling and pathological examination. C57BL/6J mice were culled using
carbon dioxide asphyxiation to avoid physical trauma to the brain. Mice were
immediately dissected and haired skin and soft tissue were removed from the cranial
surface. Incisions throughout the parietal and frontal sutures were performed to
allow fast penetration of the fixative solution into the brain parenchyma. The head
was immersed in 250mL of 10% neutral buffered formalin and fixed for 2 weeks.
After complete fixation, the brains were removed from the skull and trimmed using
a mouse brain matrix (BSMYS001-1; Zivic Instruments, Pittsburgh, PA). Four
coronal sections were obtained at the level of the pyriform cortex, caudal dience-
phalon, caudal mesencephalon and rostral cerebellum. Tissue samples were routi-
nely processed for paraffin embedding, sectioned at 4 μm, and stained with
haematoxylin and eosin. The histopathologic criteria described in the INHAND
diagnostic scheme was consulted to identify possible microscopic changes55. His-
topathological examination of brains was performed by a board-certified veterinary
pathologist.
Blood biochemical marker assays. Plasma ALT and AST activities were measured
using Alanine Transaminase Activity Assay Kit (Abcam, Cat No.: ab105134) and
AST Activity Assay Kit (Sigma-Aldrich, Cat No.: MAK055-1KT) respectively,
according to the manufacturer’s instructions.
Statistical analyses. All data are expressed as mean ± SEM and each statistical
analysis is detailed in the figure legend. Data were collected in Excel (version
16.16.26) and all statistical analyses were performed using GraphPad Prism 8
(version 8.3.1) software. Unpaired Student’s t test was performed to compare two
groups to each other. If the variance between the two groups was unequal, a
Welch’s correction was applied. To compare more than two groups, statistical
significance was determined using one-way ANOVA with Tukey’s multiple com-
parison test. For tumour volume and body weight analyses, two-way ANOVA plus
Tukey’s post hoc test were performed. p value below 0.05 was considered statis-
tically significant. Significance is indicated as follows: *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001, ns: no significance. All measurements were taken from
distinct samples. Sample sizes were based on standard protocols in the field and the
metabolic samples were assigned in a random order before analysis. Mice were
randomly assigned to a treatment and the identity of each mouse was blinded when
measurements were collected.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. All the other data supporting the findings of
this study are available within the article and its supplementary information files and
from the corresponding author upon reasonable request. Source data are provided with
this paper.
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